Nutritional and metabolic issues in solid organ transplantation: targets for future research
- PMID: 19121784
- DOI: 10.1053/j.jrn.2008.10.020
Nutritional and metabolic issues in solid organ transplantation: targets for future research
Abstract
Cardiovascular morbidity and mortality complicates the course of a significant proportion of renal transplant recipients and is increasingly prevalent among recipients of other solid organ transplants, such as heart or liver transplant patients. A posttransplant metabolic syndrome comprised of hypertension, dyslipidemia, increased fat mass/obesity, and glucose intolerance, combined with other metabolic side effects derived from glucocorticoid and calcineurin inhibitor immunosuppression, attenuates allograft and patient survival. After the early posttransplant years, infection and rejection are the major risks that recipients face, whereas metabolic and cardiovascular disease become the most serious long term risk factors impacting patient survival. While significant advances in immunosuppressive therapy have prolonged the allograft and patient survival in solid organ transplant recipients, little has been done in the way of controlled interventional trials utilizing nutritional, dietary, or biobehavioral modification, especially when combined with drug treatment to reduce the effects of the posttransplant metabolic syndrome. In addition to cardiovascular morbidity, metabolic bone disease, osteopenia, and impaired growth in children pose significant challenges in posttransplant management. In this review, the data from some of the known observational dietary trials in solid organ transplant recipients and prior evidence obtained from studies in chronic kidney disease and the general population is considered in formulating new targets for future research to deal with this ever-increasing population of high risk patients.
Similar articles
-
Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant.Exp Clin Transplant. 2008 Mar;6(1):42-7. Exp Clin Transplant. 2008. PMID: 18405244
-
Management strategies for posttransplant hypertension.Transplantation. 2000 Dec 15;70(11 Suppl):SS64-9. Transplantation. 2000. PMID: 11152234 Review.
-
Cardiac allograft vasculopathy after heart transplantation: risk factors and management.J Heart Lung Transplant. 2004 May;23(5 Suppl):S187-93. doi: 10.1016/j.healun.2004.03.009. J Heart Lung Transplant. 2004. PMID: 15093804 Review.
-
New-onset diabetes after transplantation.J Heart Lung Transplant. 2004 May;23(5 Suppl):S194-201. doi: 10.1016/j.healun.2004.03.007. J Heart Lung Transplant. 2004. PMID: 15093805 Review.
-
Transplant-associated hyperglycemia.Transplant Rev (Orlando). 2008 Jan;22(1):39-51. doi: 10.1016/j.trre.2007.06.001. Transplant Rev (Orlando). 2008. PMID: 18631857 Review.
Cited by
-
Is Intestinal Dysbiosis-Associated With Immunosuppressive Therapy a Key Factor in the Pathophysiology of Post-Transplant Diabetes Mellitus?Front Endocrinol (Lausanne). 2022 Jul 7;13:898878. doi: 10.3389/fendo.2022.898878. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35872991 Free PMC article.
-
Efficacy of dietary interventions in end-stage renal disease patients; a systematic review.J Nephropharmacol. 2015 Oct 1;5(1):28-40. eCollection 2016. J Nephropharmacol. 2015. PMID: 28197497 Free PMC article. Review.
-
Long-term dietary habits and interventions in solid-organ transplantation.J Heart Lung Transplant. 2015 Nov;34(11):1357-65. doi: 10.1016/j.healun.2015.06.014. Epub 2015 Jul 6. J Heart Lung Transplant. 2015. PMID: 26250965 Free PMC article. Review.
-
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up.J Transplant. 2010;2010:402750. doi: 10.1155/2010/402750. Epub 2010 Jul 28. J Transplant. 2010. PMID: 20706667 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical